Results 191 to 200 of about 48,236 (239)
Inhibitory effects of cefotaxime on the activity of mushroom tyrosinase [PDF]
Journal of Bioscience and Bioengineering, 2016 Tyrosinase (EC 1.14.18.1) catalyzes both the hydroxylation of tyrosine into o-diphenols and the oxidation of o-diphenols into o-quinones that form brown or black pigments.
Yong-Hua Hu +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates
Journal of Antimicrobial Chemotherapy, 1984Cefotaxime was given to neonates as treatment of infection in a dose of 25 mg/kg 12 hourly by intravenous injection. Blood samples taken by heel-prick were specially treated to minimize any effect of haemolysis on the hydrolysis of cefotaxime. The mean peak plasma concentrations of cefotaxime on the first, second and third days of therapy were 43, 40 ...
J, Crooks +4 more
openaire +2 more sources
The action of -lactamases on desacetyl-cefotaxime and cefotaxime
Journal of Antimicrobial Chemotherapy, 1984Desacetyl-cefotaxime is the main cefotaxime metabolite. Its antibacterial activity is less than that of the parent molecule, but the combination of cefotaxime and desacetyl-cefotaxime is often synergistic. We analysed the hydrolysis of desacetyl-cefotaxime, in comparison with cefotaxime, by 10 beta-lactamases, mostly cephalosporinases, isolated from ...
R, Labia, A, Morand, A, Kazmierczak
openaire +2 more sources
Pharmacokinetics of Cefotaxime and Desacetyl-Cefotaxime in Cirrhosis of the Liver
Chemotherapy, 2009In 9 patients with advanced hepatic cirrhosis and a normal serum creatinine concentration, the pharmacokinetics of cefotaxime (CTX) and its desacetyl metabolite (DACM) were examined in serum and urine after intravenous administration of 2.0 g CTX. The peak serum levels were 130.3 ± 33.9 and 8.5 ± 4.6 mg/l for CTX and DACM, respectively.
G, Höffken +4 more
openaire +2 more sources
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment
Clinical Pharmacology and Therapeutics, 1985Cefotaxime and desacetyl cefotaxime kinetics after a single, 1 gm intravenous dose were evaluated in five groups of subjects: group I, normal creatinine clearance (CLCR greater than 90 ml/min); group II, mild renal insufficiency (CLCR 30 to 89 ml/min); group III, moderate renal insufficiency (CLCR 16 to 29 ml/min); group IV, severe renal insufficiency (
G R, Matzke +3 more
openaire +2 more sources
Reactions Weekly, 2010
Cefotaxime is a third-generation or extended-spectrum cephalosporin which was developed in the 1970s and approved by the US Food and Drug Administration (FDA) in 1981. Cefotaxime is (6R,7R)-3-(acetyloxymethyl)-7- [[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid; its formula is
Kim, Baek-Nam, Paterson, David L.
openaire +3 more sources
Cefotaxime is a third-generation or extended-spectrum cephalosporin which was developed in the 1970s and approved by the US Food and Drug Administration (FDA) in 1981. Cefotaxime is (6R,7R)-3-(acetyloxymethyl)-7- [[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid; its formula is
Kim, Baek-Nam, Paterson, David L.
openaire +3 more sources